Hematology/Oncology

Top Story

Zoledronic acid reduces skeletal complications for men with progressive bony prostate cancer

Zoledronic acid reduces skeletal complications for men with progressive bony prostate cancer
May 3, 2016

The addition of zoledronic acid to docetaxel significantly reduced the rate of skeletal-related events but did not prolong OS or clinical PFS among men with metastatic castrate-refractory prostate cancer, according to results of the TRAPEZE study.

Further, the addition of strontium-89 to docetaxel appeared to improve clinical PFS but had no effect on OS or skeletal-related events, results showed.

Meeting News CoverageVideo

VIDEO: Copper depletion affects tumor microenvironment in patients at high risk for breast cancer recurrence

May 3, 2016
NEW ORLEANS — Linda T. Vahdat, MD, MBA, medical oncologist and director of the breast cancer research program at Weill Cornell Medicine and NewYork-Presbyterian…

AMA, ACP applaud CMS Medicare proposals

May 3, 2016
The AMA and the American College of Physicians have announced their support of a proposal to modernize Medicare payments.CMS issued the proposal as a first step in…

Vanderbilt University Medical Center names executive vice president for research

May 3, 2016
Jennifer Pietenpol, PhD, has been named executive vice president for research at Vanderbilt University Medical Center.Pietenpol will continue to serve as director of…

Radiopaque bead treatment at Mount Sinai ‘potential game-changer’ for hepatocellular carcinoma

May 3, 2016
An estimated 746,000 deaths occur annually from liver cancer worldwide.Few surgical options are considered beneficial in patients with intermediate- or advanced-stage…
More News Headlines »
CME

The Patient with Castration-resistant Prostate Cancer

No commercial support for this activity.

Castration-resistant prostate cancer (CRPC) is a heterogeneous condition that encompasses a continuum of disease…
More »
Video

VIDEO: Intraoperative radiation therapy provides options for patients with breast cancer

May 2, 2016
More »
Featured
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan